Alnylam Pharmaceuticals, Inc. provided earnings guidance for the year 2021. For the year, the company expects net revenues from collaborations and royalties of $150 million to $200 million. Combined net product revenues for ONPATTRO, GIVLAARI and OXLUMO of $640 million to $665 million.